Expression of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Receptor 2 in Endometrial Carcinoma
DOI:
https://doi.org/10.52206/jsmc.2024.14.4.940Keywords:
endometrial carcinoma, ER, PR, HER-2 IHC, RMIAbstract
Background: Endometrial cancer EC is the most common gynecologic malignancy diagnosed globally as well as in South Asia, with most cases diagnosed as low-grade, early-stage disease. Although most patients get cured with current treatment strategies, a subset of patients develop recurrent disease. Detailed and extensive studies performed by researcher in the past. Briefly an EC is one of the common cancers of the uterus. It arises from continuous endometrial proliferation due to estrogen stimulation; mainly in postmenopausal life.
Objective: To evaluate the expression of ER, PR and HER2 in Endometrial Carcinoma
Materials and Methods: This was a prospective, observational study conducted at the Histopathology department, RMI the largest public sector tertiary care hospital in Peshawar, from 20th May 2023 to 20th march 2024. A non-probability purposive sampling technique was used to include 32 cases of EC. The specimens were tested for ER, PR and HER-2 expression using immunohistochemical analysis. Data was analyzed in SPSS and the significance of association of expression of the receptors with histological types, grades and stages of the tumor was assessed.
Results: Significant association of Her-2 overexpression with histological types and grades of EC was seen, whereas the association of ER and PR expression with histological types, grades and stage of EC was statistically insignificant.
Conclusion: This study investigated the status of ER, PR, and HER-2 in Endometrial Cancer at RMI KPK. The results showed that ER and PR positivity was consistently high in Type-I EC, consistent with literature. HER-2 positivity was associated with more aggressive features.
Keywords: Endometrial Carcinoma, ER, PR, HER-2
References
Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010;111:215-20. PMID: 20593959
PrzewoŸny S, Rogaliñski J, de Mezer M, Markowska A, Markowska J, ¯urawski J. Estrogen Receptor ER and Progesterone Receptor PgR Expression in Endometrial CancerAn Immunohistochemical Assessment. Diagnostics. 2024;143:322. DOI: https://doi.org/10.3390/diagnostics14030322
Cagnacci A, Londero AP. Hormone therapy in endometrial cancer survivors: time for a change. Gynecol Endocrinol. 2022;3810:7956. DOI: https://doi.org/10.1080/09513590.2022.2128105
Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. J Cancer. 2020;117:1693. DOI: https://doi.org/10.7150/jca.41943
Cagnacci A, Londero AP. Hormone therapy in endometrial cancer survivors: time for a change. Gynecol Endocrinol. 2022;3810:7956. DOI: https://doi.org/10.1080/09513590.2022.2128105
Mahdy H, Casey MJ, Crotzer D. Endometrial Cancer. In: StatPearls. StatPearls Publishing; 2021.
Recent Multiomics Approaches in Endometrial Cancer. Int J Mol Sci. 2022;233:123-7. DOI: https://doi.org/10.3390/ijms23031237
Waqar S, Khan SA, Sarfraz T, Waqar S. Expression of Estrogen Receptors ER, Progesterone Receptors PR and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor. Pak J Med Sci. 2018;342:266. DOI: https://doi.org/10.12669/pjms.342.13637
Kong W, Tu Y, Jiang P, Huang Y, Zhang J, Jiang S, et al. Development and Validation of a Nomogram Involving Immunohistochemical Markers for Prediction of Recurrence in Early Low-Risk Endometrial Cancer. Int J Biol Markers. 2022;374:395-403. DOI: https://doi.org/10.1177/03936155221132292
Modi RD. The cancer genome atlas-TCGA molecular classification: A changing paradigm in the management of endometrial cancers. Current Medicine Research and Practice. 2023;132:69-73. DOI: https://doi.org/10.4103/cmrp.cmrp_125_22
Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;1533:487-95. DOI: https://doi.org/10.1016/j.ygyno.2019.03.098
Tong N, Kumar A, Gelowitz G, Tinker A, Holloway C, Ko J. Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients. Frontiers in Oncology. 2023;13:1035511. DOI: https://doi.org/10.3389/fonc.2023.1035511
Khan S, Varricchio A, Ricciardelli C, Yool AJ. Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses. Frontiers in Oncology. 2023;12:1015708. DOI: https://doi.org/10.3389/fonc.2022.1015708
Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. Journal of Cancer. 2020;117:1693. DOI: https://doi.org/10.7150/jca.41943
Tomica D, Ramiæ S, Danoliæ D, Šušnjar L, Periæ-Balja M, Puljiz M. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. J Obstet Gynaecol. 2018;381:96-102. DOI: https://doi.org/10.1080/01443615.2017.1328591
Gupta PK, Singh S, Gupta R, Lal P, Rastogi N. A Fifteen Years Audit of Endometrial Cancer Referred for Adjuvant Treatment to a Tertiary Care Hospital in Northern India. Journal of Clinical & Diagnostic Research. 2023;177. DOI: https://doi.org/10.7860/JCDR/2023/63369.18095
Lapinska-Szumczyk S, Supernat A, Majewska H, Gulczynski J, Luczak A, Biernat W, et al. HER2-Positive Endometrial Cancer Subtype Carries Poor Prognosis. Clin Transl Sci. 2014;76:482-8. DOI: https://doi.org/10.1111/cts.12207
Triarico S, Capozza MA, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Gynecological cancer among adolescents and young adults AYA. Annals of translational medicine. 2020;86. DOI: https://doi.org/10.21037/atm.2020.02.41
Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010;111:215-20. PMID: 20593959
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;2215:312632. DOI: https://doi.org/10.1200/JCO.2004.11.154
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;85:12719. PMID: 12006548
Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TM, Zipponi M, et al. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology. 202;1662:351-7. DOI: https://doi.org/10.1016/j.ygyno.2022.05.021
Díaz-Montes TP, Ji H, Sehdev AES, Zahurak ML, Kurman RJ, Armstrong DK, et al. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol. 2006;1001: 139-44. DOI: https://doi.org/10.1016/j.ygyno.2005.08.017
Shen F, Gao Y, Ding J, Chen Q. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 2017;81:506-511. DOI: https://doi.org/10.18632/oncotarget.13471 PMID: 27888807; PMCID: PMC5352172.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
